Pharma Lynx, LLC

pharmalynx.com

At Pharma Lynx, we emphasize long-term, value added relationships with a commitment to understand our customer’s business needs. By leveraging proven industry expertise, we concentrate on providing comprehensive Clinical Trials & Data Management Services to the pharmaceutical, biotechnology, generic drug, and medical device companies in the areas of Oncology, Central Nervous System (CNS), Infectious Disease & Vaccines therapeutic areas. Services Offered by Pharma Lynx: - Clinical Development Plan - Site selection - Clinical monitoring - Medical monitoring - Safety monitoring - Data Management/EDC - Biostatistics Analysis - What makes Pharma Lynx unique from other CROs? Data management is a core service of Pharma Lynx and a critical element of our customer value proposition. Pharma Lynx is headquartered out of Princeton, New Jersey, USA with an offshore office in Noida, India, and an exclusive partnership in Munich, Germany.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

news image

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More

BUSINESS INSIGHTS

VERIZON BUSINESS SELECTED TO TRANSFORM ASTELLAS PHARMA’S GLOBAL NETWORK INFRASTRUCTURE

Verizon Sourcing LLC | August 10, 2022

news image

Verizon Business has been selected to manage Astellas Pharma Inc’s global network infrastructure. The network transformation will enable Astellas to harness advanced technologies to help reduce drug development timelines, healthcare costs and drive new revenue opportunities for the Japanese pharmaceutical multinational. Headquartered in Tokyo, Japan, Astellas is a global pharmaceutical company involved in the research, development, manufacture, and marketing of innovative ne...

Read More

PHARMACY MARKET

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

news image

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More

PHARMA TECH

SALARIUS PHARMACEUTICALS AND VOLITIONRX ENTER INTO R&D COLLABORATION AGREEMENT

Salarius Pharmaceuticals, Inc. | August 03, 2022

news image

Salarius Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited a multinational epigenetics company, today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reve...

Read More
news image

AZ RECRUITS IMAGINAB IN CD8 IMMUNOPET DEAL

PharmaTimes | March 30, 2020

AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology. The companies say that under the terms of the agreement, the technology will be used in AstraZeneca’s clinical trials in Europe and North America to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET. CD8 ImmunoPET ...

Read More
news image

BUSINESS INSIGHTS

VERIZON BUSINESS SELECTED TO TRANSFORM ASTELLAS PHARMA’S GLOBAL NETWORK INFRASTRUCTURE

Verizon Sourcing LLC | August 10, 2022

Verizon Business has been selected to manage Astellas Pharma Inc’s global network infrastructure. The network transformation will enable Astellas to harness advanced technologies to help reduce drug development timelines, healthcare costs and drive new revenue opportunities for the Japanese pharmaceutical multinational. Headquartered in Tokyo, Japan, Astellas is a global pharmaceutical company involved in the research, development, manufacture, and marketing of innovative ne...

Read More
news image

PHARMACY MARKET

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More
news image

PHARMA TECH

SALARIUS PHARMACEUTICALS AND VOLITIONRX ENTER INTO R&D COLLABORATION AGREEMENT

Salarius Pharmaceuticals, Inc. | August 03, 2022

Salarius Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited a multinational epigenetics company, today announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q® technology to support further development of Salarius’ clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reve...

Read More